ATI-2231 in Advanced Solid Tumor Malignancies

NCT ID: NCT05791474

Last Updated: 2023-11-29

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-15
• Study Completion Date: 2025-06-30

Brief Summary

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

Conditions

Advanced Solid Tumor; Advanced Solid Tumor Malignancies

Keywords

MK2 inhibitor; ATI-2231

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ATI-2231 monotherapy dose escalation

• Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day.
• Each cycle is 21 days

Group Type: EXPERIMENTAL

ATI-2231

Intervention Type: DRUG

Provided by Aclaris Therapeutics, Inc.

Interventions

ATI-2231

Provided by Aclaris Therapeutics, Inc.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Biopsy-proven advanced solid tumor malignancy including head and neck cancer, non-small cell lung cancer, gastrointestinal adenocarcinoma, pancreatic adenocarcinoma, prostate cancer, bladder cancer, and breast cancer.
• Eligible patients must have an advanced solid malignancy above, for which standard curative or palliative therapies do not exist or are no longer effective.
• Measurable or non-measurable but evaluable disease by RECIST v 1.1.
• Patients must have archival tissue sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.
• At least 18 years of age.
• ECOG performance status ≤ 2
• Life expectancy of at least 12 weeks.
• Adequate bone marrow and organ function as defined below:

• Leukocytes ≥ 3 K/cumm
• Absolute neutrophil count (ANC) ≥ 1.5 K/cumm
• Platelets ≥ 100 K/cumm
• Total bilirubin ≤ 1.5 x IULN (unless patient has known Gilberts disease)
• AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
• Creatinine clearance > 60 mL/min by Cockcroft-Gault
• The effects of ATI-2231on the developing human fetus are unknown. For this reason, women of childbearing potential and men who are heterosexually active must agree to use adequate contraception as specified in the protocol. Contraception should continue for 1 month (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria

• Patients may not have received the following investigational or SOC therapies within the below specified time frames prior to C1D1:

• Denosumab or bisphosphonates within 4 weeks
• Radiation therapy within 1 week
• Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
• Immunotherapy within 3 weeks
• Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
• Endocrine therapies do not have a required washout and may be continued until C1D1.
• Untreated brain metastases. Patients with treated brain metastases are eligible if they show no evidence of progression and are off steroids or on stable/decreasing steroid dose.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ATI-2231.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Patients with known HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
• Screening resting QTcF above 460 ms (average of triplicate).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aclaris Therapeutics, Inc.

INDUSTRY

Sponsor Role: collaborator

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cynthia X Ma, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Countries

United States

Related Links

http://www.siteman.wustl.edu

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Other Identifiers

202306048

Identifier Type: -

Identifier Source: org_study_id